3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow peginterferon lambda-1a: new trials by email Literature Review of peginterferon lambda-1a trials Research Report on peginterferon lambda-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients Peginterferon lambda - Hepatitis C | Phase 1 | Completed | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 60 | 2013-12-01 | 2016-12-15 |
| Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction BMS-914143 (Peginterferon Lambda-1a) - Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection | Phase 1 | Completed | Bristol-Myers Squibb | 43 | 2012-09-01 | 2013-06-05 |
| Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection PEGylated recombinant interleukin 29 (PEG-rIL-29) - Hepatitis C, Chronic | Phase 1 | Completed | ZymoGenetics | 56 | 2007-12-01 | 2009-10-07 |
Hepatitis C (2) · Hepatitis B, Chronic (1) · Hepatitis C, Chronic (1) · Infections (1) · Virus Diseases (1)
Bristol-Myers Squibb (1) · Nanogen Pharmaceutical Biotechnology Joint Stock Company (1) · ZymoGenetics (1)
United States (2) · Canada (1) · Vietnam (1)